Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).
Clinical Benefit
| Low |
the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo. |
Clinical Added Value
| no clinical added value |
VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V). |
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
mYnjVQDJ2ne6QxkL
Listen
